The REALITY study is a prospective, post-market, non-randomized, multi-center, single-arm, open-label study intended to collect short- and long-term safety and effectiveness data on various populations implanted with Abbott's neurostimulation systems.
This study has broad inclusion criteria and minimal exclusion criteria to ensure the results are representative of the real-world use of these devices. Enrollment caps will be implemented to ensure patients from approved indications are represented. Individuals who are scheduled to receive an implantable Abbott neurostimulation system are eligible for study consideration. The study will enroll up to 2,000 subjects from up to 100 participating centers. Subject enrollment is expected to be completed within 7 years; subjects will be followed for 5 years. The total duration of the study is expected to be 13 years, including enrollment, data collection from all subjects, and study close out.
Study Type
OBSERVATIONAL
Enrollment
2,000
Subjects will be implanted with market-released Abbott SCS systems
Subjects will be implanted with market-released Abbott DRG system
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: Baseline
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: Permanent Implant Procedure
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 6 months
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 9 months
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Phoenician Centers for Research & Innovation
Phoenix, Arizona, United States
TERMINATEDPain Institute of Southern Arizona
Tucson, Arizona, United States
TERMINATEDCalifornia Orthopedics & Spine
Larkspur, California, United States
TERMINATEDRestore Orthopedics & Spine Center
Orange, California, United States
TERMINATEDFoothills Pain Management Clinic
Pomona, California, United States
TERMINATEDPacific Research Institute
Santa Rosa, California, United States
TERMINATEDUniversity of Florida Department of Anesthesia
Gainesville, Florida, United States
TERMINATEDRush University Medical Center
Chicago, Illinois, United States
ACTIVE_NOT_RECRUITINGUniversity of Chicago
Chicago, Illinois, United States
ACTIVE_NOT_RECRUITINGGoodman Campbell Brain and Spine
Indianapolis, Indiana, United States
ACTIVE_NOT_RECRUITING...and 45 more locations
Time frame: 1 Year
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 1.5 Years
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 2 Years
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 2.5 Years
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 3 Years
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 3.5 Years
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 4 Years
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 4.5 Years
Rate of device and procedure related adverse events, deaths, and device deficiencies
Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.
Time frame: 5 Years